Atopic Dermatitis (Eczema)
61
9
14
30
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
13 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
6.6%
4 terminated out of 61 trials
88.2%
+1.7% vs benchmark
21%
13 trials in Phase 3/4
43%
13 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (61)
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Seal, Stopping Eczema and Allergy Study
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time
The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Tofacitinib for Immune Skin Conditions in Down Syndrome
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Moisturization and Skin Hydration Study
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
Topical ENS-002 for Atopic Dermatitis in Adults
Validation Of A Parent Administered Symptom Score For Unsettled Infants (Every Baby is UnIQue)
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.